Dengue Clinical Trial - Study of Yellow Fever Vaccine Administered With

Status Completed

Clinical Trial Summary

The study was designed to evaluate whether the first CYD dengue vaccination can be administered concomitantly with Stamaril® yellow fever vaccine during the same day and visit, but at 2 different sites of administration. Primary Objective: - To demonstrate the non-inferiority of the immune response against Yellow Fever (YF) in flavivirus (FV) non-immune subjects at baseline receiving one dose of Stamaril vaccine administered concomitantly with the first dose of CYD dengue vaccine compared to participants receiving one dose of Stamaril vaccine concomitantly with placebo. Secondary Objectives: - To assess the non-inferiority of YF immune response 28 days post-Stamaril vaccination based on seroconversion rates regardless of the FV status of participants at baseline. - To describe the YF immune response 28 days post-Stamaril vaccination in both groups. - To describe the antibody (Ab) response to each dengue virus serotype 28 days post CYD dengue vaccine (Visit [V] 05 and V07), following CYD dengue vaccine Dose 1 and Dose 2 from Group 2 versus following CYD dengue vaccine Dose 2 and Dose 3 for Group 1 (effect of YF vaccination). - To describe the safety of Stamaril vaccine administered concomitantly with the first dose of CYD dengue vaccine, or Stamaril administered concomitantly with placebo. - To describe the safety of CYD dengue vaccine after the first dose of CYD dengue vaccine administered concomitantly with Stamaril vaccine or CYD vaccine administered alone. - To describe the safety of the CYD dengue vaccine in all participants after each dose.

Clinical Trial Description

All participants received a total of 9 injections during the study. Vaccine immunogenicity assessments for dengue neutralizing antibodies was performed in a randomized subset of participants. All participants were followed-up for safety during the study and for 6 months after the last CYD dengue vaccination. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01436396
Study type	Interventional
Source	Sanofi
Contact
Status	Completed
Phase	Phase 3
Start date	September 7, 2011
Completion date	September 2, 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05321264` - Educational Intervention to Promote Control Behaviors and Prevention of Dengue	N/A
Completed	`NCT01391819` - Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children	N/A
Completed	`NCT03641339` - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans	N/A
Completed	`NCT02833584` - Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults	N/A
Completed	`NCT02433652` - Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2	Phase 1
Enrolling by invitation	`NCT02016027` - Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter	Phase 1
Completed	`NCT01477671` - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children	N/A
Recruiting	`NCT00377754` - Prospective Study of Infant Dengue	N/A
Recruiting	`NCT05919277` - A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
Recruiting	`NCT04582474` - Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso	N/A
Completed	`NCT01983553` - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed	`NCT03803618` - Dengue Effectiveness Study in the Philippines
Active, not recruiting	`NCT05967455` - Homologous Re-infection With Dengue 1 or Dengue 3	Phase 1
Completed	`NCT03631719` - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Recruiting	`NCT02606019` - The Use of Biomarkers in Predicting Dengue Outcome	N/A
Completed	`NCT02372175` - Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain	Phase 1
Active, not recruiting	`NCT01696422` - Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine	Phase 2
Completed	`NCT00993447` - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America	Phase 2
Completed	`NCT00375726` - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults	Phase 1
Completed	`NCT05153018` - Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms